Effects of ibopamine on serum prolactin and growth hormone levels in hyperprolactinemic and acromegalic subjects.
The effects of oral doses (100, 200, and 400 mg) of a dopamine derivative, ibopamine, on serum prolactin (PRL) and growth hormone (GH) levels were evaluated in hyperprolactinemic patients, some of whom also were acromegalic. There was dose-related lowering of PRL levels. The highest dose was as effective as 500 mg L-dopa, although the duration of action was shorter, with a decrease to below 50% of basal PRL values in all patients. Serum GH did not rise in nonacromegalic subjects, but it fell after 400 mg ibopamine in the L-dopa-sensitive acromegalic patients. These data suggest, but do not prove, that ibopamine is able to directly stimulate pituitary dopamine receptors.
D000172:Acromegaly / Q000097:blood*; D000293:Adolescent; D000328:Adult; D003846:Deoxyepinephrine / Q000031:analogs & derivatives* / Q000494:pharmacology; D004298:Dopamine / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D005260:Female; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007980:Levodopa / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood*
D007980:Levodopa; C023487:ibopamine; D011388:Prolactin; D013006:Growth Hormone; D003846:Deoxyepinephrine; D004298:Dopamine